HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pan-Chyr Yang Selected Research

Erlotinib Hydrochloride (CP 358,774)

5/2011Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations.
4/2008Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.
12/2007MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Pan-Chyr Yang Research Topics

Disease

145Neoplasms (Cancer)
01/2024 - 02/2002
91Lung Neoplasms (Lung Cancer)
11/2023 - 11/2002
90Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2023 - 02/2002
69Adenocarcinoma of Lung
11/2023 - 11/2002
41Neoplasm Metastasis (Metastasis)
10/2023 - 11/2002
21Adenocarcinoma
10/2017 - 11/2002
19Carcinogenesis
01/2022 - 11/2002
11Infections
11/2021 - 01/2002
10Tuberculosis (Tuberculoses)
01/2016 - 09/2004
9Hypoxia (Hypoxemia)
11/2018 - 08/2005
9Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/2018 - 07/2005
8Pneumonia (Pneumonitis)
01/2014 - 06/2004
7Severe Acute Respiratory Syndrome
01/2022 - 10/2004
7Disease Progression
01/2021 - 10/2004
7Lung Injury
01/2019 - 11/2006
7Pneumothorax
04/2018 - 02/2002
7Carcinoma (Carcinomatosis)
06/2015 - 07/2003
7Lymphatic Metastasis
08/2014 - 11/2002
7Chronic Obstructive Pulmonary Disease (COPD)
01/2014 - 09/2006
6Inflammation (Inflammations)
06/2015 - 08/2005
5Lung Diseases (Lung Disease)
11/2023 - 04/2003
5Sepsis (Septicemia)
01/2022 - 08/2005
5Hemorrhage
04/2018 - 10/2004
4Pulmonary Tuberculosis
11/2023 - 01/2010
4Respiratory Insufficiency (Respiratory Failure)
06/2022 - 12/2003
4Melanoma (Melanoma, Malignant)
12/2020 - 08/2015
4Malignant Pleural Effusion
07/2017 - 04/2011
4Sarcoma (Soft Tissue Sarcoma)
04/2016 - 05/2014
4Lymphoma (Lymphomas)
04/2016 - 01/2012
4Lymphopenia (Lymphocytopenia)
06/2015 - 05/2004
4Breast Neoplasms (Breast Cancer)
04/2013 - 06/2003
4Critical Illness (Critically Ill)
08/2010 - 08/2004
3COVID-19
04/2024 - 01/2022
3Virus Diseases (Viral Diseases)
04/2024 - 01/2014
3Brain Neoplasms (Brain Tumor)
02/2018 - 01/2008
3Hepatocellular Carcinoma (Hepatoma)
01/2014 - 02/2003
3Pleural Effusion (Pleural Effusions)
05/2012 - 04/2005

Drug/Important Bio-Agent (IBA)

56ErbB Receptors (EGF Receptor)IBA
01/2023 - 02/2006
43Proteins (Proteins, Gene)FDA Link
01/2023 - 11/2002
31Tyrosine Kinase InhibitorsIBA
01/2023 - 12/2008
29Gefitinib (Iressa)FDA Link
11/2019 - 06/2005
18Biomarkers (Surrogate Marker)IBA
10/2023 - 04/2008
16MicroRNAs (MicroRNA)IBA
10/2023 - 07/2006
15DNA (Deoxyribonucleic Acid)IBA
11/2023 - 12/2006
14Messenger RNA (mRNA)IBA
06/2015 - 02/2002
13CytokinesIBA
01/2021 - 10/2004
10AntigensIBA
01/2020 - 07/2003
10Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
03/2016 - 02/2002
10Interleukin-8 (Interleukin 8)IBA
06/2015 - 02/2002
9Anti-Bacterial Agents (Antibiotics)IBA
01/2022 - 09/2003
9Small Interfering RNA (siRNA)IBA
01/2022 - 12/2006
9Pemetrexed (MTA)FDA Link
11/2020 - 02/2011
8ParaffinIBA
03/2017 - 06/2011
7EnzymesIBA
11/2021 - 10/2005
7Interleukin-6 (Interleukin 6)IBA
01/2019 - 02/2005
7Protein Isoforms (Isoforms)IBA
03/2016 - 01/2004
7NF-kappa B (NF-kB)IBA
01/2013 - 02/2003
6SmokeIBA
11/2023 - 08/2010
6CurcuminIBA
01/2023 - 01/2004
6AntibodiesIBA
01/2023 - 06/2005
6Phosphotransferases (Kinase)IBA
01/2021 - 12/2007
6LigandsIBA
01/2021 - 01/2005
6Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2015 - 03/2004
5Immune Checkpoint InhibitorsIBA
01/2023 - 01/2020
5Cadherins (E-Cadherin)IBA
01/2019 - 06/2005
5RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
07/2017 - 02/2005
5C-Reactive ProteinIBA
12/2012 - 12/2003
5collapsin response mediator protein-1IBA
01/2012 - 01/2003
5InterleukinsIBA
10/2005 - 03/2004
4VaccinesIBA
01/2022 - 01/2014
4Cisplatin (Platino)FDA LinkGeneric
04/2020 - 04/2007
4ChemokinesIBA
01/2019 - 11/2006
4PlatinumIBA
03/2017 - 11/2008
4Anaplastic Lymphoma KinaseIBA
01/2017 - 05/2014
4CateninsIBA
08/2014 - 08/2012
4GemcitabineFDA Link
08/2012 - 01/2008
3osimertinibIBA
01/2023 - 01/2018
3InterferonsIBA
01/2022 - 06/2006
3LipopolysaccharidesIBA
01/2022 - 07/2002
3Peptides (Polypeptides)IBA
04/2021 - 08/2007
3Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2020 - 01/2016
3Thymidylate SynthaseIBA
09/2017 - 10/2011
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
10/2016 - 05/2011
3AfatinibIBA
03/2016 - 05/2012
3CarcinogensIBA
02/2016 - 08/2010
3Antiviral Agents (Antivirals)IBA
01/2016 - 01/2014
3Membrane Proteins (Integral Membrane Proteins)IBA
12/2015 - 07/2003
3Minocycline (Cyclops)FDA LinkGeneric
07/2014 - 11/2008
3IntegrinsIBA
01/2013 - 03/2004
3Bevacizumab (Avastin)FDA Link
08/2012 - 02/2011

Therapy/Procedure

61Therapeutics
04/2024 - 04/2003
25Drug Therapy (Chemotherapy)
04/2020 - 12/2002
10Immunotherapy
01/2024 - 05/2014
7Pleurodesis
07/2014 - 02/2002
6Radiotherapy
07/2020 - 01/2008
5Chest Tubes (Chest Tube)
04/2018 - 08/2002
5Artificial Respiration (Mechanical Ventilation)
01/2009 - 04/2003
4Aftercare (After-Treatment)
04/2020 - 03/2006
4Hormone Replacement Therapy (Therapy, Hormone Replacement)
10/2015 - 10/2007
3Adjuvant Chemotherapy
08/2014 - 04/2013